Argent Advisors Inc. Has $2.31 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Argent Advisors Inc. lowered its position in Pfizer Inc. (NYSE:PFE - Free Report) by 12.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 86,960 shares of the biopharmaceutical company's stock after selling 12,178 shares during the period. Pfizer comprises 0.9% of Argent Advisors Inc.'s holdings, making the stock its 29th largest position. Argent Advisors Inc.'s holdings in Pfizer were worth $2,307,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in PFE. Swedbank AB increased its position in shares of Pfizer by 0.7% in the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company's stock valued at $166,284,000 after buying an additional 37,636 shares in the last quarter. United Bank increased its position in shares of Pfizer by 3.7% in the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company's stock valued at $1,030,000 after buying an additional 1,277 shares in the last quarter. Vaughan Nelson Investment Management L.P. increased its position in shares of Pfizer by 15.4% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 88,670 shares of the biopharmaceutical company's stock valued at $2,566,000 after buying an additional 11,820 shares in the last quarter. Chesapeake Capital Corp IL bought a new stake in shares of Pfizer in the 3rd quarter valued at $293,000. Finally, Thrivent Financial for Lutherans boosted its stake in Pfizer by 14.5% in the 3rd quarter. Thrivent Financial for Lutherans now owns 846,582 shares of the biopharmaceutical company's stock worth $24,500,000 after purchasing an additional 107,346 shares during the period. Institutional investors own 68.36% of the company's stock.

Remove Ads

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.06% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on PFE shares. StockNews.com lowered shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 20th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Bank of America restated a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Truist Financial reduced their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. Finally, Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, Pfizer has a consensus rating of "Moderate Buy" and a consensus price target of $31.92.

Pfizer Stock Performance

Pfizer stock traded down $0.11 during trading hours on Wednesday, hitting $26.21. The company had a trading volume of 24,966,825 shares, compared to its average volume of 35,756,685. The firm has a market cap of $148.51 billion, a PE ratio of 18.58, a PEG ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The firm has a 50-day moving average of $26.21 and a 200 day moving average of $27.09.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same period last year, the firm earned $0.10 earnings per share. The business's revenue for the quarter was up 24.7% on a year-over-year basis. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.